{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:06:51Z","timestamp":1772777211599,"version":"3.50.1"},"reference-count":136,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Remission failure and relapse numerate as one of the main problems in patients with\nantineutrophil cytoplasmic antibody-associated vasculitis (AAVs). The need for new agents that\nprovide effective and safe induction accompanied by sustained remission seems to be urgent in\nclinical care. The efficacy and safety of rituximab (RTX) for AAVs therapy has been reported in\nvarious studies. RTX therapy offers several advantages to treating AAVs patients compared to\nother therapeutic approaches including reduction of Glucocorticoids (GCs) and conventional Immunosuppressive\ntherapy (IST) usage during both the induction of remission and maintenance\nphases. This reduction can lead to a lower rate of serious complications making RTX therapy a\nsafer option. It seems that RTX may provide improved clinical outcomes in these patients mediated\nvia B-lymphocyte depletion, Proteinase 3-antineutrophilic cytoplasmic antibody (PR3-ANCA),\nand myeloperoxidase-antineutrophilic cytoplasmic antibody (MPO-ANCA) titers reduction. In\nthis regard, some uncertainties have been reported to validate the association between such depletion\nand clinical improvement, as suggested by other sources of autoreactive B cells that did not\ntarget with RTX. Due to the prolonged B cell depletion, fixed intervals and adjusted dosage of\nRTX may be required in patients with AAVs. In this narrative review, we aimed to insight better\nunderstand regarding the efficacy of RTX for effective induction and sustained remission in patients\nwith AAVs. It seems that discovering new biomarkers predicting relapse in AAVs patients\ncan lead to future targeted therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113894501323529240910015912","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T10:58:12Z","timestamp":1727261892000},"page":"73-87","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":true,"given":"Mohammad Amin","family":"Habibi","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-874X","authenticated-orcid":true,"given":"Sajjad","family":"Ahmadpour","sequence":"additional","affiliation":[{"name":"Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad","family":"Tafaroji","sequence":"additional","affiliation":[{"name":"Pediatric Medicine\nResearch Center, Qom University of Medical Sciences, Qom, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad","family":"Eazi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Qom University of Medical Sciences, Qom, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poriya","family":"Minaee","sequence":"additional","affiliation":[{"name":"Student Research Committee, Qom University of Medical Sciences, Qom, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Mohammadpour","sequence":"additional","affiliation":[{"name":"Patient Safety\nResearch Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran"},{"name":"Department of Medical Education, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8830","authenticated-orcid":true,"given":"Soheil","family":"Tavakolpour","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5114\/ceji.2019.92494","volume":"45","author":"Fijo\u0142ek J.","year":"2020","unstructured":"Fijo\u0142ek J.; Wiatr E.; Antineutrophil cytoplasmic antibodies \u2013 Their role in pathogenesis, diagnosis and treatment monitoring of ANCA-associated vasculitis. Cent Eur J Immunol  2020,45(2),218-227","journal-title":"Cent Eur J Immunol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"m1070","DOI":"10.1136\/bmj.m1070","volume":"369","author":"Hunter R.W.","year":"2020","unstructured":"Hunter R.W.; Welsh N.; Farrah T.E.; Gallacher P.J.; Dhaun N.; ANCA associated vasculitis. Br Med J  2020,369,m1070","journal-title":"Br Med J"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.37765\/ajmc.2021.88746","volume":"27","author":"Koening C.L.","year":"2021","unstructured":"Koening C.L.; von Hennigs I.; Antineutrophil cytoplasmic antibody (ANCA) vasculitis: Pathophysiology, diagnosis, and the evolving treatment landscape. Am J Manag Care  2021,27(15),S267-S276","journal-title":"Am J Manag Care"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"Watts R.A.","year":"2022","unstructured":"Watts R.A.; Hatemi G.; Burns J.C.; Mohammad A.J.; Global epidemiology of vasculitis. Nat Rev Rheumatol  2022,18(1),22-34","journal-title":"Nat Rev Rheumatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"w14103","DOI":"10.4414\/smw.2015.14103","volume":"145","author":"Daikeler T.","year":"2015","unstructured":"Daikeler T.; Kistler A.D.; Martin P.Y.; Vogt B.; Huynh-Do U.; The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). Swiss Med Wkly  2015,145,w14103","journal-title":"Swiss Med Wkly"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/1529-0131(200102)44:2<463::AID-ANR65>3.0.CO;2-9","volume":"44","author":"Russell K.A.","year":"2001","unstructured":"Russell K.A.; Fass D.N.; Specks U.; Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener\u2019s granulomatosis and microscopic polyangiitis. Arthritis Rheum  2001,44(2),463-468","journal-title":"Arthritis Rheum"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/1759720X13516239","volume":"6","author":"Clain J.M.","year":"2014","unstructured":"Clain J.M.; Cartin-Ceba R.; Fervenza F.C.; Specks U.; Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Ther Adv Musculoskelet Dis  2014,6(2),58-74","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12882-023-03075-8","volume":"24","author":"Liu L.","year":"2023","unstructured":"Liu L.; Lu H.; Zou G.; Wang H.; Li J.; Yang Y.; Zhang J.; Wang X.; Li W.; Zhuo L.; Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: A Chinese case series. BMC Nephrol  2023,24(1),28","journal-title":"BMC Nephrol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1093\/rheumatology\/keac046","volume":"61","author":"Morel P.","year":"2022","unstructured":"Morel P.; Karras A.; Porcher R.; Belenfant X.; Audard V.; Rafat C.; Hanouna G.; Beaudreuil S.; Vilain C.; Hummel A.; Terrier B.; Pillebout E.; Groh M.; Jouenne R.; Dhote R.; Fain O.; Ponsoye M.; Noel N.; Limal N.; Pu\u00e9chal X.; Le Jeunne C.; Guillevin L.; Mouthon L.; R\u00e9gent A.; Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: The place of rituximab and plasma exchange? Rheumatology (Oxford)  2022,61(10),4056-4064","journal-title":"Rheumatology (Oxford)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/art.42002","volume":"74","author":"Jain S.","year":"2022","unstructured":"Jain S.; Naidu G.S.R.S.N.K.; Sharma A.; Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody\u2013associated vasculitis: Comment on the article by Chung et al. Arthritis Rheumatol  2022,74(3),544-545","journal-title":"Arthritis Rheumatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5414\/CP204053","volume":"60","author":"Lee Y.H.","year":"2022","unstructured":"Lee Y.H.; Song G.G.; Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized co. Int J Clin Pharmacol Ther  2022,60(2),97-105","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","volume":"34","author":"Martinez Del Pero M.","year":"2009","unstructured":"Martinez Del Pero M.; Chaudhry A.; Jones R.B.; Sivasothy P.; Jani P.; Jayne D.; B-cell depletion with rituximab for refractory head and neck Wegener\u2019s granulomatosis: A cohort study. Clin Otolaryngol  2009,34(4),328-335","journal-title":"Clin Otolaryngol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"Jones R.B.","year":"2010","unstructured":"Jones R.B.; Cohen Tervaert J.W.; Hauser T.; Luqmani R.; Morgan M.D.; Peh C.A.; Savage C.O.; Segelmark M.; Tesar V.; van Paassen P.; Walsh D.; Walsh M.; Westman K.; Jayne D.R.W.; Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med  2010,363(3),211-220","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"Specks U.","year":"2013","unstructured":"Specks U.; Merkel P.A.; Seo P.; Spiera R.; Langford C.A.; Hoffman G.S.; Kallenberg C.G.; St Clair E.W.; Fessler B.J.; Ding L.; Viviano L.; Tchao N.K.; Phippard D.J.; Asare A.L.; Lim N.; Ikle D.; Jepson B.; Brunetta P.; Allen N.B.; Fervenza F.C.; Geetha D.; Keogh K.; Kissin E.Y.; Monach P.A.; Peikert T.; Stegeman C.; Ytterberg S.R.; Mueller M.; Sejismundo L.P.; Mieras K.; Stone J.H.; Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med  2013,369(5),417-427","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/art.38744","volume":"66","author":"Azar L.","year":"2014","unstructured":"Azar L.; Springer J.; Langford C.A.; Hoffman G.S.; Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener\u2019s): a retrospective single-center study. Arthritis Rheumatol  2014,66(10),2862-2870","journal-title":"Arthritis Rheumatol"},{"key":"ref=16","first-page":"S155","volume":"35","author":"Lionaki S.","year":"2017","unstructured":"Lionaki S.; Fragoulis GE.; Venetsanopoulou A.; Vlachoyiannopoulos P.; Boletis JN.; Tzioufas AG.; Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol  2017,35((Suppl 103)),S155-S164","journal-title":"Clin Exp Rheumatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000329535","volume":"34","author":"Roccatello D.","year":"2011","unstructured":"Roccatello D.; Sciascia S.; Rossi D.; Alpa M.; Naretto C.; Russo A.; Menegatti E.; Baldovino S.; Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol  2011,34(2),175-180","journal-title":"Am J Nephrol"},{"key":"ref=18","first-page":"S54","volume":"34","author":"Pugnet G.","year":"2016","unstructured":"Pugnet G.; Pagnoux C.; Terrier B.; Perrodeau E.; Pu\u00e9chal X.; Karras A.; Khouatra C.; Auma\u00eetre O.; Cohen P.; Maurier F.; Decaux O.; Ninet J.; Gobert P.; Quemeneur T.; Blanchard-Delaunay C.; Godmer P.; Carron P.L.; Hatron P.Y.; Limal N.; Hamidou M.; Ducret M.; Daugas E.; Papo T.; Bonnotte B.; Mahr A.; Ravaud P.; Mouthon L.; Guillevin L.; Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. Clin Exp Rheumatol  2016,34(3),S54-S59","journal-title":"Clin Exp Rheumatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"Yates M.","year":"2016","unstructured":"Yates M.; Watts R.A.; Bajema I.M.; Cid M.C.; Crestani B.; Hauser T.; Hellmich B.; Holle J.U.; Laudien M.; Little M.A.; Luqmani R.A.; Mahr A.; Merkel P.A.; Mills J.; Mooney J.; Segelmark M.; Tesar V.; Westman K.; Vaglio A.; Yal\u00e7\u0131nda\u011f N.; Jayne D.R.; Mukhtyar C.; EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis  2016,75(9),1583-1594","journal-title":"Ann Rheum Dis"},{"key":"ref=20","first-page":"137","volume":"37","author":"Montante A.","year":"2019","unstructured":"Montante A.; Le Bras A.; Pagnoux C.; Perrodeau E.; Ravaud P.; Terrier B.; Guillevin L.; Durand-Zaleski I.; Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol  2019,37(2),137-143","journal-title":"Clin Exp Rheumatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2215\/CJN.08821209","volume":"5","author":"Rhee E.P.","year":"2010","unstructured":"Rhee E.P.; Laliberte K.A.; Niles J.L.; Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol  2010,5(8),1394-1400","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/art.39104","volume":"67","author":"Miloslavsky E.M.","year":"2015","unstructured":"Miloslavsky E.M.; Specks U.; Merkel P.A.; Seo P.; Spiera R.; Langford C.A.; Hoffman G.S.; Kallenberg C.G.; St Clair E.W.; Tchao N.K.; Ding L.; Ikl\u00e9 D.; Villareal M.; Lim N.; Brunetta P.; Fervenza F.C.; Monach P.A.; Stone J.H.; Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol  2015,67(6),1629-1636","journal-title":"Arthritis Rheumatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"Holle J.U.","year":"2012","unstructured":"Holle J.U.; Dubrau C.; Herlyn K.; Heller M.; Ambrosch P.; Noelle B.; Reinhold-Keller E.; Gross W.L.; Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis  2012,71(3),327-333","journal-title":"Ann Rheum Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/14397595.2020.1790778","volume":"31","author":"Takeyama Y.","year":"2021","unstructured":"Takeyama Y.; Ono N.; Shirahama Y.; Inoue Y.; Tanaka A.; Ueda N.; Nishimura N.; Nagano S.; Uchino A.; Miyamura T.; Oryoji K.; Inoue H.; Maruyama A.; Ota S.; Yoshizawa S.; Sawabe T.; Himuro N.; Miyake K.; Kimoto Y.; Horiuchi T.; Mitoma H.; Niiro H.; Takamori A.; Tada Y.; Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan. Mod Rheumatol  2021,31(2),408-416","journal-title":"Mod Rheumatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3899\/jrheum.190019","volume":"47","author":"Weiner M.","year":"2020","unstructured":"Weiner M.; Goh S.M.; Mohammad A.J.; Hru\u0161kov\u00e1 Z.; Tanna A.; Sharp P.; Kang A.; Bruchfeld A.; Selga D.; Chocov\u00e1 Z.; Westman K.; Eriksson P.; Harper L.; Pusey C.D.; Tesa\u0159 V.; Salama A.D.; Segelmark M.; Effect of treatment on damage and hospitalization in elderly patients with microscopic polyangiitis and granulomatosis with polyangiitis. J Rheumatol  2020,47(4),580-588","journal-title":"J Rheumatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3899\/jrheum.210537","volume":"48","author":"Mendel A.","year":"2021","unstructured":"Mendel A.; Pagnoux C.; Use of rituximab for the treatment of antineutrophil cytoplasm antibody\u2013associated vasculitis in Canada, 2010\u20132020. J Rheumatol  2021,48(11),1755-1756","journal-title":"J Rheumatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/acr.23142","volume":"69","author":"James K.E.","year":"2017","unstructured":"James K.E.; Xiao R.; Merkel P.A.; Weiss P.F.; Variation in the treatment of children hospitalized with antineutrophil cytoplasmic antibody\u2013associated vasculitis in the US. Arthritis Care Res (Hoboken)  2017,69(9),1377-1383","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/art.39562","volume":"68","author":"Cartin-Ceba R.","year":"2016","unstructured":"Cartin-Ceba R.; Diaz-Caballero L.; Al-Qadi M.O.; Tryfon S.; Fervenza F.C.; Ytterberg S.R.; Specks U.; Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody\u2013associated vasculitis: Predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol  2016,68(6),1467-1476","journal-title":"Arthritis Rheumatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/17843286.2019.1578041","volume":"75","author":"Chasseur P.","year":"2020","unstructured":"Chasseur P.; Blockmans D.; von Frenckell C.; Nicolas J-B.; Regniers C.; Vandergheynst F.; Rituximab prescription patterns and efficacy in the induction treatment of ANCA-associated vasculitis in a Belgian multicenter cohort. Acta Clin Belg  2020,75(3),163-169","journal-title":"Acta Clin Belg"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ndt\/gfx378","volume":"34","author":"McAdoo S.P.","year":"2019","unstructured":"McAdoo S.P.; Medjeral-Thomas N.; Gopaluni S.; Tanna A.; Mansfield N.; Galliford J.; Griffith M.; Levy J.; Cairns T.D.; Jayne D.; Salama A.D.; Pusey C.D.; Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant  2019,34(1),63-73","journal-title":"Nephrol Dial Transplant"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","volume":"53","author":"Charles P.","year":"2014","unstructured":"Charles P.; N\u00e9el A.; Tieuli\u00e9 N.; Hot A.; Pugnet G.; Decaux O.; Marie I.; Khellaf M.; Kahn J.E.; Karras A.; Ziza J.M.; Deligny C.; Tch\u00e9rakian C.; Guillevin L.; Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford)  2014,53(3),532-539","journal-title":"Rheumatology (Oxford)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2215\/CJN.07340713","volume":"9","author":"Pendergraft W.F.","year":"2014","unstructured":"Pendergraft W.F.; Cortazar F.B.; Wenger J.; Murphy A.P.; Rhee E.P.; Laliberte K.A.; Niles J.L.; Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol  2014,9(4),736-744","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","volume":"50","author":"Calich A.L.","year":"2014","unstructured":"Calich A.L.; Pu\u00e9chal X.; Pugnet G.; London J.; Terrier B.; Charles P.; Mouthon L.; Guillevin L.; Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener\u2019s). Results of a single-center cohort study on 66 patients. J Autoimmun  2014,50,135-141","journal-title":"J Autoimmun"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/acr2.11274","volume":"3","author":"B\u00e9nard V.","year":"2021","unstructured":"B\u00e9nard V.; Farhat C.; Zarandi-Nowroozi M.; Durand M.; Charles P.; Pu\u00e9chal X.; Guillevin L.; Pagnoux C.; Makhzoum J.P.; Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody\u2013associated vasculitis: Systematic review and meta-analysis. ACR Open Rheumatol  2021,3(7),484-494","journal-title":"ACR Open Rheumatol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"Smith R.M.","year":"2012","unstructured":"Smith R.M.; Jones R.B.; Guerry M.J.; Laurino S.; Catapano F.; Chaudhry A.; Smith K.G.C.; Jayne D.R.W.; Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheum  2012,64(11),3760-3769","journal-title":"Arthritis Rheum"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10067-013-2351-y","volume":"33","author":"Knight A.","year":"2014","unstructured":"Knight A.; Hallenberg H.; Baecklund E.; Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis - A case series. Clin Rheumatol  2014,33(6),841-848","journal-title":"Clin Rheumatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/rheumatology\/key117","volume":"58","author":"Pu\u00e9chal X.","year":"2019","unstructured":"Pu\u00e9chal X.; Iudici M.; Calich A.L.; Vivot A.; Terrier B.; R\u00e9gent A.; Cohen P.; Jeunne C.L.; Mouthon L.; Ravaud P.; Guillevin L.; Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: A single-centre cohort study on 114 patients. Rheumatology (Oxford)  2019,58(3),401-409","journal-title":"Rheumatology (Oxford)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e222092","DOI":"10.1001\/jamanetworkopen.2022.20925","volume":"5","author":"Thietart S","year":"2022","unstructured":"Thietart S; Karras A; Augusto J-F; Philipponnet C; Carron P-L; Delbrel X; Mesbah R; Blaison G; Duffau P; El Karoui K; Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody-associated vasculitis. JAMA Netw Open  2022,5(7),e222092","journal-title":"JAMA Netw Open"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","volume":"52","author":"Besada E.","year":"2013","unstructured":"Besada E.; Koldingsnes W.; Nossent J.C.; Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: Results from a single centre. Rheumatology (Oxford)  2013,52(11),2041-2047","journal-title":"Rheumatology (Oxford)"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"Harper L.","year":"2012","unstructured":"Harper L.; Morgan M.D.; Walsh M.; Hoglund P.; Westman K.; Flossmann O.; Tesar V.; Vanhille P.; Groot K.; Luqmani R.; Flores-Suarez L.F.; Watts R.; Pusey C.; Bruchfeld A.; Rasmussen N.; Blockmans D.; Savage C.O.; Jayne D.; Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis  2012,71(6),955-960","journal-title":"Ann Rheum Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"Stone J.H.","year":"2010","unstructured":"Stone J.H.; Merkel P.A.; Spiera R.; Seo P.; Langford C.A.; Hoffman G.S.; Kallenberg C.G.; St Clair E.W.; Turkiewicz A.; Tchao N.K.; Webber L.; Ding L.; Sejismundo L.P.; Mieras K.; Weitzenkamp D.; Ikle D.; Seyfert-Margolis V.; Mueller M.; Brunetta P.; Allen N.B.; Fervenza F.C.; Geetha D.; Keogh K.A.; Kissin E.Y.; Monach P.A.; Peikert T.; Stegeman C.; Ytterberg S.R.; Specks U.; Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med  2010,363(3),221-232","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"i123","DOI":"10.1093\/ndt\/gfv076","volume":"30","author":"McGregor JG","year":"2015","unstructured":"McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ; Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant  2015,30(suppl 1),i123-i131","journal-title":"Nephrol Dial Transplant"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","volume":"54","author":"Alberici F.","year":"2015","unstructured":"Alberici F.; Smith R.M.; Jones R.B.; Roberts D.M.; Willcocks L.C.; Chaudhry A.; Smith K.G.C.; Jayne D.R.W.; Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford)  2015,54(7),1153-1160","journal-title":"Rheumatology (Oxford)"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"Cartin-Ceba R.","year":"2012","unstructured":"Cartin-Ceba R.; Golbin J.M.; Keogh K.A.; Peikert T.; S\u00e1nchez-Men\u00e9ndez M.; Ytterberg S.R.; Fervenza F.C.; Specks U.; Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): Ten-year experience at a single center. Arthritis Rheum  2012,64(11),3770-3778","journal-title":"Arthritis Rheum"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","volume":"26","author":"Mansfield N.","year":"2011","unstructured":"Mansfield N.; Hamour S.; Habib A.M.; Tarzi R.; Levy J.; Griffith M.; Cairns T.; Cook H.T.; Pusey C.D.; Salama A.D.; Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant  2011,26(10),3280-3286","journal-title":"Nephrol Dial Transplant"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00296-012-2587-x","volume":"33","author":"Braun-Moscovici Y.","year":"2013","unstructured":"Braun-Moscovici Y.; Butbul-Aviel Y.; Guralnik L.; Toledano K.; Markovits D.; Rozin A.; Nahir M.A.; Balbir-Gurman A.; Rituximab: Rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int  2013,33(6),1495-1504","journal-title":"Rheumatol Int"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3899\/jrheum.110143","volume":"39","author":"Roubaud-Baudron C.","year":"2012","unstructured":"Roubaud-Baudron C.; Pagnoux C.; M\u00e9aux-Ruault N.; Grasland A.; Zoulim A.; Le Guen J.; Prud\u2019Homme A.; Bienvenu B.; de Menthon M.A.T.H.I.L.D.E.; Camps S.; Le Guern V.; Aouba A.; Cohen P.; Mouthon L.; Guillevin L.; Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol  2012,39(1),125-130","journal-title":"J Rheumatol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"Jones R.B.","year":"2009","unstructured":"Jones R.B.; Ferraro A.J.; Chaudhry A.N.; Brogan P.; Salama A.D.; Smith K.G.C.; Savage C.O.S.; Jayne D.R.W.; A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheum  2009,60(7),2156-2168","journal-title":"Arthritis Rheum"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10067-020-05261-7","volume":"40","author":"Mittal S.","year":"2021","unstructured":"Mittal S.; Naidu G.S.R.S.N.K.; Jha S.; Rathi M.; Nada R.; Minz R.W.; Sharma K.; Dhir V.; Jain S.; Sharma A.; Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis - A real-life experience. Clin Rheumatol  2021,40(2),645-651","journal-title":"Clin Rheumatol"},{"key":"ref=50","first-page":"S23","volume":"25","author":"Brihaye B.","year":"2007","unstructured":"Brihaye B.; Aouba A.; Pagnoux C.; Cohen P.; Lacassin F.; Guillevin L.; Adjunction of rituximab to steroids and immunosuppressants for refractory\/relapsing Wegener\u2019s granulomatosis: A study on 8 patients. Clin Exp Rheumatol  2007,25(1),S23-S27","journal-title":"Clin Exp Rheumatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s10067-011-1756-8","volume":"30","author":"Rees F.","year":"2011","unstructured":"Rees F.; Yazdani R.; Lanyon P.; Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol  2011,30(9),1241-1245","journal-title":"Clin Rheumatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"Charles P.","year":"2018","unstructured":"Charles P.; Terrier B.; Perrodeau \u00c9.; Cohen P.; Faguer S.; Huart A.; Hamidou M.; Agard C.; Bonnotte B.; Samson M.; Karras A.; Jourde-Chiche N.; Lifermann F.; Gobert P.; Hanrotel-Saliou C.; Godmer P.; Martin-Silva N.; Pugnet G.; Matignon M.; Aumaitre O.; Viallard J.F.; Maurier F.; Meaux-Ruault N.; Rivi\u00e8re S.; Sibilia J.; Pu\u00e9chal X.; Ravaud P.; Mouthon L.; Guillevin L.; Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis  2018,77(8),1143-1149","journal-title":"Ann Rheum Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1002\/art.38788","volume":"66","author":"Miloslavsky E.M.","year":"2014","unstructured":"Miloslavsky E.M.; Specks U.; Merkel P.A.; Seo P.; Spiera R.; Langford C.A.; Hoffman G.S.; Kallenberg C.G.M.; St Clair E.W.; Tchao N.K.; Viviano L.; Ding L.; Ikl\u00e9 D.; Villarreal M.; Jepson B.; Brunetta P.; Allen N.B.; Fervenza F.C.; Geetha D.; Keogh K.; Kissin E.Y.; Monach P.A.; Peikert T.; Stegeman C.; Ytterberg S.R.; Stone J.H.; Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol  2014,66(11),3151-3159","journal-title":"Arthritis Rheumatol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ndt\/gfn430","volume":"24","author":"Lovric S.","year":"2008","unstructured":"Lovric S.; Erdbruegger U.; K\u00fcmpers P.; Woywodt A.; Koenecke C.; Wedemeyer H.; Haller H.; Haubitz M.; Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: A single-centre experience with 15 patients. Nephrol Dial Transplant  2008,24(1),179-185","journal-title":"Nephrol Dial Transplant"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/rheumatology\/kez632","volume":"59","author":"Tieu J.","year":"2020","unstructured":"Tieu J.; Smith R.; Basu N.; Brogan P.; D\u2019Cruz D.; Dhaun N.; Flossmann O.; Harper L.; Jones R.B.; Lanyon P.C.; Luqmani R.A.; McAdoo S.P.; Mukhtyar C.; Pearce F.A.; Pusey C.D.; Robson J.C.; Salama A.D.; Smyth L.; Watts R.A.; Willcocks L.C.; Jayne D.R.W.; Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines-Executive summary. Rheumatology (Oxford)  2020,59(4),727-731","journal-title":"Rheumatology (Oxford)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/ard.2005.044420","volume":"65","author":"Aries P.M.","year":"2005","unstructured":"Aries P.M.; Hellmich B.; Voswinkel J.; Both M.; N\u00f6lle B.; Holl-Ulrich K.; Lamprecht P.; Gross W.L.; Lack of efficacy of rituximab in Wegener\u2019s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis  2005,65(7),853-858","journal-title":"Ann Rheum Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/s10165-008-0119-z","volume":"19","author":"Ooka S.","year":"2009","unstructured":"Ooka S.; Maeda A.; Ito H.; Omata M.; Yamada H.; Ozaki S.; Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener\u2019s granulomatosis: A case report. Mod Rheumatol  2009,19(1),80-83","journal-title":"Mod Rheumatol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/846063","volume":"2010","author":"Khan A.","year":"2010","unstructured":"Khan A.; Lawson C.A.; Quinn M.A.; Isdale A.H.; Green M.J.; Successful treatment of ANCA-negative wegener\u2019s granulomatosis with rituximab. Int J Rheumatol  2010,2010,1-2","journal-title":"Int J Rheumatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e0182549","DOI":"10.1371\/journal.pone.0182549","volume":"12","author":"Land J.","year":"2017","unstructured":"Land J.; Abdulahad W.H.; Arends S.; Sanders J.S.F.; Stegeman C.A.; Heeringa P.; Rutgers A.; Prospective monitoring of in vitro produced PR3-ANCA does not improve relapse prediction in granulomatosis with polyangiitis. PLoS One  2017,12(8),e0182549","journal-title":"PLoS One"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","volume":"19","author":"Thiel J.","year":"2017","unstructured":"Thiel J.; Rizzi M.; Engesser M.; Dufner A.K.; Troilo A.; Lorenzetti R.; Voll R.E.; Venhoff N.; B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: A longitudinal observational study on 120 patients. Arthritis Res Ther  2017,19(1),101","journal-title":"Arthritis Res Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13075-019-2054-0","volume":"21","author":"Urlaub D.","year":"2019","unstructured":"Urlaub D.; Zhao S.; Blank N.; Bergner R.; Claus M.; Tretter T.; Lorenz H.M.; Watzl C.; Merkt W.; Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Arthritis Res Ther  2019,21(1),277","journal-title":"Arthritis Res Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"Smith R.M.","year":"2020","unstructured":"Smith R.M.; Jones R.B.; Specks U.; Bond S.; Nodale M.; Aljayyousi R.; Andrews J.; Bruchfeld A.; Camilleri B.; Carette S.; Cheung C.K.; Derebail V.; Doulton T.; Forbess L.; Fujimoto S.; Furuta S.; Gewurz-Singer O.; Harper L.; Ito-Ihara T.; Khalidi N.; Klocke R.; Koening C.; Komagata Y.; Langford C.; Lanyon P.; Luqmani R.A.; Makino H.; McAlear C.; Monach P.; Moreland L.W.; Mynard K.; Nachman P.; Pagnoux C.; Pearce F.; Peh C.A.; Pusey C.; Ranganathan D.; Rhee R.L.; Spiera R.; Sreih A.G.; Tesar V.; Walters G.; Weisman M.H.; Wroe C.; Merkel P.; Jayne D.; Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis  2020,79(9),1243-1249","journal-title":"Ann Rheum Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1093\/ndt\/gfn318","volume":"23","author":"Ferraro A.J.","year":"2008","unstructured":"Ferraro A.J.; Smith S.W.; Neil D.; Savage C.O.S.; Relapsed Wegener\u2019s granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent \u2018depletion\u2019 of peripheral blood. Nephrol Dial Transplant  2008,23(9),3030-3032","journal-title":"Nephrol Dial Transplant"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"Venhoff N.","year":"2012","unstructured":"Venhoff N.; Effelsberg N.M.; Salzer U.; Warnatz K.; Peter H.H.; Lebrecht D.; Schlesier M.; Voll R.E.; Thiel J.; Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One  2012,7(5),e37626","journal-title":"PLoS One"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/25785826.2022.2094592","volume":"45","author":"Tsuboi K.","year":"2022","unstructured":"Tsuboi K.; Noguchi K.; Kitano M.; Furukawa T.; Hashimoto T.; Azuma N.; Matsui K.; Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis. Immunol Med  2022,45(4),238-243","journal-title":"Immunol Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/08916934.2014.914174","volume":"47","author":"Venhoff N.","year":"2014","unstructured":"Venhoff N.; Niessen L.; Kreuzaler M.; Rolink A.G.; H\u00e4ssler F.; Rizzi M.; Voll R.E.; Thiel J.; Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity  2014,47(6),401-408","journal-title":"Autoimmunity"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3899\/jrheum.210361","volume":"48","author":"Springer J.M.","year":"2021","unstructured":"Springer J.M.; Funk R.S.; Dose-dependent pharmacological response to rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol  2021,48(11),1718-1724","journal-title":"J Rheumatol"},{"key":"ref=68","first-page":"002448","volume":"8","author":"Diegues A.","year":"2021","unstructured":"Diegues A.; Tavares J.; S\u00e1 D.; Oliveira J.; Fernandes D.; Santos J.; Rocha G.; Granulomatosis with polyangiitis: Recurrence or treatment consequences? Eur J Case Rep Intern Med  2021,8(4),002448","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"566732","DOI":"10.3389\/fimmu.2020.566732","volume":"11","author":"van Dam L.S.","year":"2020","unstructured":"van Dam L.S.; Oskam J.M.; Kamerling S.W.A.; Arends E.J.; Bredewold O.W.; Berkowska M.A.; van Dongen J.J.M.; Rabelink T.J.; van Kooten C.; Teng Y.K.O.; Highly sensitive flow cytometric detection of residual B-cells after rituximab in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients. Front Immunol  2020,11,566732","journal-title":"Front Immunol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/art.38916","volume":"67","author":"Unizony S.","year":"2015","unstructured":"Unizony S.; Lim N.; Phippard D.J.; Carey V.J.; Miloslavsky E.M.; Tchao N.K.; Ikl\u00e9 D.; Asare A.L.; Merkel P.A.; Monach P.A.; Seo P.; St Clair E.W.; Langford C.A.; Spiera R.; Hoffman G.S.; Kallenberg C.G.; Specks U.; Stone J.H.; Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol  2015,67(2),535-544","journal-title":"Arthritis Rheumatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10067-014-2816-7","volume":"34","author":"Chocova Z.","year":"2015","unstructured":"Chocova Z.; Hruskova Z.; Mareckova H.; Svobodova B.; Duskova D.; Bednarova V.; Jancova E.; Rysava R.; Tesar V.; Rituximab use in patients with ANCA-associated vasculitis: Clinical efficacy and impact on immunological parameters. Clin Rheumatol  2015,34(1),107-115","journal-title":"Clin Rheumatol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/ckj\/sfz029","volume":"12","author":"Martinez Valenzuela L.","year":"2019","unstructured":"Martinez Valenzuela L.; Bordignon Draibe J.; Fulladosa Oliveras X.; Bestard Matamoros O.; Cruzado Garrit J.M.; Torras Ambr\u00f3s J.; T-lymphocyte in ANCA-associated vasculitis: What do we know? A pathophysiological and therapeutic approach. Clin Kidney J  2019,12(4),503-511","journal-title":"Clin Kidney J"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/art.38107","volume":"65","author":"M\u00e9let J.","year":"2013","unstructured":"M\u00e9let J.; Mulleman D.; Goupille P.; Ribourtout B.; Watier H.; Thibault G.; Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum  2013,65(11),2783-2790","journal-title":"Arthritis Rheum"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.7717\/peerj.2487","volume":"4","author":"Besada E.","year":"2016","unstructured":"Besada E.; Nossent J.C.; CD4 cell count and CD4\/CD8 ratio increase during rituximab maintenance in Granulomatosis with polyangiitis patients. PeerJ  2016,4,e2487","journal-title":"PeerJ"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/rheumatology\/ket406","volume":"53","author":"Zhao Y.","year":"2014","unstructured":"Zhao Y.; Lutalo P.M.K.; Thomas J.E.; Sangle S.; Choong L.M.; Tyler J.R.; Tree T.; Spencer J.; D\u2019Cruz D.P.; Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B cell depletion in patients with granulomatosis with polyangiitis. Rheumatology (Oxford)  2014,53(4),621-630","journal-title":"Rheumatology (Oxford)"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13075-016-1098-7","volume":"18","author":"Merkt W.","year":"2016","unstructured":"Merkt W.; Claus M.; Blank N.; Hundemer M.; Cerwenka A.; Lorenz H.M.; Watzl C.; Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells. Arthritis Res Ther  2016,18(1),204","journal-title":"Arthritis Res Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13075-016-1101-3","volume":"18","author":"Merkt W.","year":"2016","unstructured":"Merkt W.; Lorenz H.M.; Watzl C.; Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting. Arthritis Res Ther  2016,18(1),206","journal-title":"Arthritis Res Ther"},{"key":"ref=78","first-page":"5","author":"Kishimoto T","year":"1992","unstructured":"Kishimoto T; Hibi M; Murakami M; Narazaki M; Saito M; Taga T; The molecular biology of interleukin 6 and its receptor. Ciba Foundation Symposium 167 - Polyfunctional Cytokines: IL-6 and LIF  1992,5-16","journal-title":"Ciba Foundation Symposium 167 - Polyfunctional Cytokines: IL-6 and LIF"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ndt\/gfx148.SP403","volume":"32","author":"Wang Q.","year":"2017","unstructured":"Wang Q.; van Timmeren M.M.; Petersen A.H.; Yuan J.; Moser J.; Brouwer E.; Westra J.; Boots A.M.H.; Heeringa P.; Age-determined severity of anti-myeloperoxidase autoantibody-mediated glomerulonephritis in mice. Nephrol Dial Transplant  2017,32(2),254-264","journal-title":"Nephrol Dial Transplant"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"102302","DOI":"10.1016\/j.jaut.2019.07.001","volume":"105","author":"Berti A.","year":"2019","unstructured":"Berti A.; Warner R.; Johnson K.; Cornec D.; Schroeder D.R.; Kabat B.F.; Langford C.A.; Kallenberg C.G.M.; Seo P.; Spiera R.F.; St Clair E.W.; Fervenza F.C.; Stone J.H.; Monach P.A.; Specks U.; Merkel P.A.; The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. J Autoimmun  2019,105,102302","journal-title":"J Autoimmun"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.berh.2007.01.004","volume":"21","author":"Nataraja A.","year":"2007","unstructured":"Nataraja A.; Mukhtyar C.; Hellmich B.; Langford C.; Luqmani R.; Outpatient assessment of systemic vasculitis. Best Pract Res Clin Rheumatol  2007,21(4),713-732","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","volume":"43","author":"Boomsma M.M.","year":"2000","unstructured":"Boomsma M.M.; Stegeman C.A.; Van Der Leij M.J.; Oost W.; Hermans J.; Kallenberg C.G.M.; Limburg P.C.; Tervaert J.W.C.; Prediction of relapses in Wegener\u2019s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum  2000,43(9),2025-2033","journal-title":"Arthritis Rheum"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.ophtha.2011.06.009","volume":"118","author":"Joshi L.","year":"2011","unstructured":"Joshi L.; Lightman S.L.; Salama A.D.; Shirodkar A.L.; Pusey C.D.; Taylor S.R.J.; Rituximab in refractory ophthalmic Wegener\u2019s granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology  2011,118(12),2498-2503","journal-title":"Ophthalmology"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","volume":"36","author":"van Dam L.S.","year":"2021","unstructured":"van Dam L.S.; Dirikgil E.; Bredewold E.W.; Ray A.; Bakker J.A.; van Kooten C.; Rabelink T.J.; Teng Y.K.O.; PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol Dial Transplant  2021,36(8),1408-1417","journal-title":"Nephrol Dial Transplant"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","volume":"25","author":"McClure M.E.","year":"2019","unstructured":"McClure M.E.; Wason J.; Gopaluni S.; Tieu J.; Smith R.M.; Jayne D.R.; Jones R.B.; Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis. J Clin Rheumatol  2019,25(5),217-223","journal-title":"J Clin Rheumatol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","volume":"147","author":"Finkielman J.D.","year":"2007","unstructured":"Finkielman J.D.; Merkel P.A.; Schroeder D.; Hoffman G.S.; Spiera R.; St Clair E.W.; Davis J.C.; McCune W.J.; Lears A.K.; Ytterberg S.R.; Hummel A.M.; Viss M.A.; Peikert T.; Stone J.H.; Specks U.; Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med  2007,147(9),611-619","journal-title":"Ann Intern Med"},{"key":"ref=87","first-page":"S38","volume":"31","author":"Rasmussen N.","year":"2013","unstructured":"Rasmussen N.; Salmela A.; Ekstrand A.; de Groot K.; Gregorini G.; Cohen Tervaert J.W.; Gross W.L.; Wiik A.; Jayne D.R.; Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener\u2019s) may reflect treatment rather than disease activity. Clin Exp Rheumatol  2013,31(1),S38-S44","journal-title":"Clin Exp Rheumatol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","volume":"75","author":"Unizony S.","year":"2016","unstructured":"Unizony S.; Villarreal M.; Miloslavsky E.M.; Lu N.; Merkel P.A.; Spiera R.; Seo P.; Langford C.A.; Hoffman G.S.; Kallenberg C.M.; St Clair E.W.; Ikle D.; Tchao N.K.; Ding L.; Brunetta P.; Choi H.K.; Monach P.A.; Fervenza F.; Stone J.H.; Specks U.; Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis  2016,75(6),1166-1169","journal-title":"Ann Rheum Dis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1136\/annrheumdis-2014-206496","volume":"74","author":"Md Yusof M.Y.","year":"2015","unstructured":"Md Yusof M.Y.; Vital E.M.; Das S.; Dass S.; Arumugakani G.; Savic S.; Rawstron A.C.; Emery P.; Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: Identifying B cell biomarkers for relapse to guide retreatment decisions. Ann Rheum Dis  2015,74(9),1734-1738","journal-title":"Ann Rheum Dis"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-020-02215-x","volume":"22","author":"Miyazaki Y.","year":"2020","unstructured":"Miyazaki Y.; Nakayamada S.; Kubo S.; Ishikawa Y.; Yoshikawa M.; Sakata K.; Iwata S.; Miyagawa I.; Nakano K.; Tanaka Y.; Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Res Ther  2020,22(1),141","journal-title":"Arthritis Res Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1136\/annrheumdis-2014-206756","volume":"74","author":"Bunch D.O.","year":"2015","unstructured":"Bunch D.O.; Mendoza C.E.; Aybar L.T.; Kotzen E.S.; Colby K.R.; Hu Y.; Hogan S.L.; Poulton C.J.; Schmitz J.L.; Falk R.J.; Nachman P.H.; Pendergraft W.F.; McGregor J.G.; Gleaning relapse risk from B cell phenotype: decreased CD5  B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis. Ann Rheum Dis  2015,74(9),1784-1786","journal-title":"Ann Rheum Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13075-015-0778-z","volume":"17","author":"Nasrallah M.","year":"2015","unstructured":"Nasrallah M.; Pouliot Y.; Hartmann B.; Dunn P.; Thomson E.; Wiser J.; Butte A.J.; Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment. Arthritis Res Ther  2015,17(1),262","journal-title":"Arthritis Res Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/art.39814","volume":"69","author":"Pepper R.J.","year":"2017","unstructured":"Pepper R.J.; Draibe J.B.; Caplin B.; Fervenza F.C.; Hoffman G.S.; Kallenberg C.G.; Langford C.A.; Monach P.A.; Seo P.; Spiera R.; William St Clair E.; Tchao N.K.; Stone J.H.; Specks U.; Merkel P.A.; Salama A.D.; Association of serum calprotectin (S100A8\/A9) level with disease relapse in proteinase 3\u2013antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheumatol  2017,69(1),185-193","journal-title":"Arthritis Rheumatol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jaci.2016.08.051","volume":"139","author":"Alberici F","year":"2017","unstructured":"Alberici F; Smith RM; Fonseca M; Willcocks LC; Jones RB; Holle JU; Wieczorek S; Neumann T; Martorana D; Gregorini G; Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody\u2013associated vasculitis. J Allergy Clin Immunol  2017,139(5),1684-1687.e10","journal-title":"J Allergy Clin Immunol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/1573397117666210726143757","volume":"17","author":"Puchala M.","year":"2021","unstructured":"Puchala M.; Rydzewski A.; Kowalik I.; Wis\u0142owska M.; Comparison of granulomatosis with polyangiitis clinical features in patients depending on involvement or absence of kidney involvement. Curr Rheumatol Rev  2021,17(4),379-389","journal-title":"Curr Rheumatol Rev"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/rheumatology\/kez071","volume":"58","author":"Durel C.A.","year":"2019","unstructured":"Durel C.A.; Hot A.; Trefond L.; Aumaitre O.; Pugnet G.; Samson M.; Abad S.; Belot A.; Blanchard-Delaunay C.; Cohen P.; Cohen-Aubard F.; Cottin V.; Crestani B.; Moreuil C.D.; Durupt S.; Garzaro M.; Girszyn N.; Godeau B.; Hachulla E.; Jamilloux Y.; Jego P.; Killian M.; Lazaro E.; Le Gallou T.; Liozon E.; Martin T.; Papo T.; Perlat A.; Pillet P.; Guillevin L.; Terrier B.; Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford)  2019,58(9),1565-1573","journal-title":"Rheumatology (Oxford)"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-3083.2012.02747.x","volume":"76","author":"Pullerits R.","year":"2012","unstructured":"Pullerits R.; Ljevak M.; Vikgren J.; Bokarewa M.; Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: Long-term follow-up from a single centre. Scand J Immunol  2012,76(4),411-420","journal-title":"Scand J Immunol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e136180","DOI":"10.1172\/jci.insight.136180","volume":"5","author":"Owczarczyk K.","year":"2020","unstructured":"Owczarczyk K.; Cascino M.D.; Holweg C.; Tew G.W.; Ortmann W.; Behrens T.; Schindler T.; Langford C.A.; St Clair E.W.; Merkel P.A.; Spiera R.; Seo P.; Kallenberg C.G.; Specks U.; Lim N.; Stone J.; Brunetta P.; Prunotto M.; Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight  2020,5(18),e136180","journal-title":"JCI Insight"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40064-015-0835-8","volume":"4","author":"Draibe J.","year":"2015","unstructured":"Draibe J.; Salama A.D.; Association of ANCA associated vasculitis and rheumatoid arthritis: A lesser recognized overlap syndrome. Springerplus  2015,4(1),50","journal-title":"Springerplus"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9340524","volume":"2016","author":"Foray N.","year":"2016","unstructured":"Foray N.; Hudali T.; Papireddy M.; Gao J.; A case report describing a rare presentation of simultaneous occurrence of MPO-ANCA-associated vasculitis and rheumatoid arthritis. Case Rep Nephrol  2016,2016,1-5","journal-title":"Case Rep Nephrol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5013904","volume":"2019","author":"Itikyala S.","year":"2019","unstructured":"Itikyala S.; Pattanaik D.; Raza S.; Systemic Lupus Erythematosus (SLE) and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) overlap syndrome: Case report and review of the literature. Case Rep Rheumatol  2019,2019,1-5","journal-title":"Case Rep Rheumatol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6690658","volume":"2021","author":"Hounoki H.","year":"2021","unstructured":"Hounoki H.; Shinoda K.; Matsui A.; Okumura M.; Yamaguchi S.; Kakeshita K.; Yamazaki H.; Koike T.; Makino T.; Tobe K.; A Case of systemic lupus erythematosus and antineutrophil cytoplasmic antibodies-associated vasculitis overlap syndrome. Case Rep Rheumatol  2021,2021,1-6","journal-title":"Case Rep Rheumatol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0961203320920368","volume":"29","author":"Farah R.I.","year":"2020","unstructured":"Farah R.I.; Shahin N.A.; Alawneh M.; Adwan M.; Rapidly progressive glomerulonephritis due to systemic lupus erythematosus and ANCA-associated vasculitis overlap. Lupus  2020,29(8),983-986","journal-title":"Lupus"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5414\/CNCS110852","volume":"10","author":"Wu H.H.L.","year":"2022","unstructured":"Wu H.H.L.; Wang C.C.Y.; Woywodt A.; Ponnusamy A.; Concurrent presentation of IgG4-related tubulointerstitial nephritis and ANCA MPO crescentic glomerulonephritis. Clin Nephrol Case Stud  2022,10(1),47-53","journal-title":"Clin Nephrol Case Stud"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3109\/08916934.2012.677078","volume":"45","author":"Szilasi M.","year":"2012","unstructured":"Szilasi M.; M\u00e1tyus J.; File I.; Sz\u00fccs G.; R\u00e1k\u00f3czi \u00c9.; Pfliegler G.; Szab\u00f3 Z.; V\u00e9gh E.; Szekanecz Z.; Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: Rituximab may be the right choice? Autoimmunity  2012,45(4),304-309","journal-title":"Autoimmunity"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000443163","volume":"6","author":"Huang J.","year":"2016","unstructured":"Huang J.; Wu L.; Huang X.; Xie Y.; Yu J.; Yang J.; Fang H.; Zhang L.; Successful treatment of dual-positive anti-myeloperoxidase and anti-glomerular basement membrane antibody vasculitis with pulmonary-renal syndrome. Case Rep Nephrol Dial  2016,6(1),1-7","journal-title":"Case Rep Nephrol Dial"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"413","DOI":"10.5414\/CN109445","volume":"90","author":"Kant S.","year":"2018","unstructured":"Kant S.; Shah A.A.; Hummers L.K.; Wigley F.M.; Geetha D.; ANCA-associated vasculitis in scleroderma: A renal perspective\u2029. Clin Nephrol  2018,90(6),413-418","journal-title":"Clin Nephrol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1753495X18780853","volume":"13","author":"Pefanis A.","year":"2020","unstructured":"Pefanis A.; Williams D.S.; Skrzypek H.; Fung A.; Paizis K.; A case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab. Obstet Med  2020,13(1),41-44","journal-title":"Obstet Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40620-020-00881-3","volume":"34","author":"Kant S.","year":"2021","unstructured":"Kant S.; Morris A.; Ravi S.; Floyd L.; Gapud E.; Antichos B.; Dhaygude A.; Seo P.; Geetha D.; The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. J Nephrol  2021,34(1),185-190","journal-title":"J Nephrol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"e26111","DOI":"10.7759\/cureus.26111","volume":"14","author":"Kataria S.","year":"2022","unstructured":"Kataria S.; Rogers S.; Sadia H.; Ali T.; Qureshi H.M.; Bano S.; Anigbo C.L.; Singh R.; Antineutrophil Cytoplasmic Antibody (ANCA)-associated renal vasculitis after COVID-19 infection: A Case report. Cureus  2022,14(6),e26111","journal-title":"Cureus"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/RHU.0000000000001855","volume":"28","author":"\u0130nce B.","year":"2022","unstructured":"\u0130nce B.; Bekta\u015f M.; Koca N.; A\u011farg\u00fcn B.F.; Zarali S.; G\u00fczey D.Y.; Durak G.; Yal\u00e7inkaya Y.; Artim-Esen B.; G\u00fcl A.; \u0130nan\u00e7 M.; Antineutrophil cytoplasmic antibody-associated vasculitis and COVID-19. J Clin Rheumatol  2022,28(6),300-304","journal-title":"J Clin Rheumatol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/annrheumdis-2020-218310","volume":"80","year":"2021","unstructured":"Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis FAI2R \/SFR\/SNFMI\/SOFREMIP\/CRI\/IMIDIATE consortium and contributors 2021,80(4),527-538","journal-title":"Ann Rheum Dis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","volume":"60","author":"McClure M.E.","year":"2021","unstructured":"McClure M.E.; Zhu Y.; Smith R.M.; Gopaluni S.; Tieu J.; Pope T.; Kristensen K.E.; Jayne D.R.W.; Barrett J.; Jones R.B.; Long-term maintenance rituximab for ANCA-associated vasculitis: Relapse and infection prediction models. Rheumatology (Oxford)  2021,60(3),1491-1501","journal-title":"Rheumatology (Oxford)"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1136\/annrheumdis-2020-218075","volume":"80","author":"Schulze-Koops H.","year":"2021","unstructured":"Schulze-Koops H.; Krueger K.; Vallbracht I.; Hasseli R.; Skapenko A.; Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis  2021,80(5),e67","journal-title":"Ann Rheum Dis"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.16896","volume":"190","author":"Tepasse P.R.","year":"2020","unstructured":"Tepasse P.R.; Hafezi W.; Lutz M.; K\u00fchn J.; Wilms C.; Wiewrodt R.; Sackarnd J.; Keller M.; Schmidt H.H.; Vollenberg R.; Persisting SARS-CoV-2 viraemia after rituximab therapy: Two cases with fatal outcome and a review of the literature. Br J Haematol  2020,190(2),185-188","journal-title":"Br J Haematol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"Strangfeld A.","year":"2021","unstructured":"Strangfeld A.; Sch\u00e4fer M.; Gianfrancesco M.A.; Lawson-Tovey S.; Liew J.W.; Ljung L.; Mateus E.F.; Richez C.; Santos M.J.; Schmajuk G.; Scir\u00e8 C.A.; Sirotich E.; Sparks J.A.; Sufka P.; Thomas T.; Trupin L.; Wallace Z.S.; Al-Adely S.; Bachiller-Corral J.; Bhana S.; Cacoub P.; Carmona L.; Costello R.; Costello W.; Gossec L.; Grainger R.; Hachulla E.; Hasseli R.; Hausmann J.S.; Hyrich K.L.; Izadi Z.; Jacobsohn L.; Katz P.; Kearsley-Fleet L.; Robinson P.C.; Yazdany J.; Machado P.M.; Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis  2021,80(7),930-942","journal-title":"Ann Rheum Dis"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","volume":"383","author":"Haberman R.","year":"2020","unstructured":"Haberman R.; Axelrad J.; Chen A.; Castillo R.; Yan D.; Izmirly P.; Neimann A.; Adhikari S.; Hudesman D.; Scher J.U.; Covid-19 in immune-mediated inflammatory diseases - Case series from New York. N Engl J Med  2020,383(1),85-88","journal-title":"N Engl J Med"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-021-03234-7","volume":"591","author":"Combes A.J.","year":"2021","unstructured":"Combes A.J.; Courau T.; Kuhn N.F.; Hu K.H.; Ray A.; Chen W.S.; Chew N.W.; Cleary S.J.; Kushnoor D.; Reeder G.C.; Shen A.; Tsui J.; Hiam-Galvez K.J.; Mu\u00f1oz-Sandoval P.; Zhu W.S.; Lee D.S.; Sun Y.; You R.; Magnen M.; Rodriguez L.; Im K.W.; Serwas N.K.; Leligdowicz A.; Zamecnik C.R.; Loudermilk R.P.; Wilson M.R.; Ye C.J.; Fragiadakis G.K.; Looney M.R.; Chan V.; Ward A.; Carrillo S.; Cathy C.; Zhan J.; Samad B.; Chak S.; Ghale R.; Giberson J.; Gonzalez A.; Jauregui A.; Lee D.; Nguyen V.; Yee K.; Abe-Jones Y.; Pierce L.; Prasad P.; Sinha P.; Beagle A.; Lea T.; Esmalii A.; Sigman A.; Ortiz G.M.; Raffel K.; Jones C.; Liu K.; Eckalbar W.; Matthay M.; Erle D.J.; Woodruff P.G.; Langelier C.; Kangelaris K.; Hendrickson C.M.; Calfee C.; Rao A.A.; Krummel M.F.; Global absence and targeting of protective immune states in severe COVID-19. Nature  2021,591(7848),124-130","journal-title":"Nature"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1136\/annrheumdis-2020-217549","volume":"80","author":"Guilpain P.","year":"2021","unstructured":"Guilpain P.; Le Bihan C.; Foulongne V.; Taourel P.; Pansu N.; Maria A.T.J.; Jung B.; Larcher R.; Klouche K.; Le Moing V.; Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: Lessons from a case with severe pneumonia. Ann Rheum Dis  2021,80(1),e10","journal-title":"Ann Rheum Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/art.41380","volume":"72","author":"Fallet B.","year":"2020","unstructured":"Fallet B.; Kyburz D.; Walker U.A.; Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment. Arthritis Rheumatol  2020,72(9),1581-1582","journal-title":"Arthritis Rheumatol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00296-021-04975-4","volume":"41","author":"Kopp C.R.","year":"2021","unstructured":"Kopp C.R.; Naidu G.S.R.S.N.K.; Misra D.P.; Deo P.; Jakulla R.S.; Makan K.; Maharaj A.; Agarwal V.; Sharma A.; Managing ANCA-associated vasculitis during the COVID-19 pandemic: Results from an online survey. Rheumatol Int  2021,41(11),1941-1947","journal-title":"Rheumatol Int"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1573397113666170517155443","volume":"13","author":"Watanabe T.","year":"2017","unstructured":"Watanabe T.; Vasculitis following influenza vaccination: A review of the literature. Curr Rheumatol Rev  2017,13(3),188-196","journal-title":"Curr Rheumatol Rev"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1093\/rheumatology\/keab175","volume":"60","author":"Quartuccio L.","year":"2021","unstructured":"Quartuccio L.; Treppo E.; Binutti M.; Del Frate G.; De Vita S.; Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology (Oxford)  2021,60(7),3476-3477","journal-title":"Rheumatology (Oxford)"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1053\/j.ajkd.2021.06.016","volume":"78","author":"Shakoor M.T.","year":"2021","unstructured":"Shakoor M.T.; Birkenbach M.P.; Lynch M.; ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis  2021,78(4),611-613","journal-title":"Am J Kidney Dis"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.kint.2021.07.026","volume":"100","author":"Villa M.","year":"2021","unstructured":"Villa M.; D\u00edaz-Crespo F.; P\u00e9rez de Jos\u00e9 A.; Verdalles \u00da.; Verde E.; Almeida Ruiz F.; Acosta A.; Mijaylova A.; Goicoechea M.; A case of ANCA-associated vasculitis after AZD1222 (Oxford\u2013AstraZeneca) SARS-CoV-2 vaccination: Casualty or causality? Kidney Int  2021,100(4),937-938","journal-title":"Kidney Int"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"765447","DOI":"10.3389\/fmed.2021.765447","volume":"8","author":"Chen C.C.","year":"2021","unstructured":"Chen C.C.; Chen H.Y.; Lu C.C.; Lin S.H.; Case Report: Anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage may occur after COVID-19 vaccination. Front Med (Lausanne)  2021,8(2195),765447","journal-title":"Front Med (Lausanne)"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","volume":"3","author":"Moor M.B.","year":"2021","unstructured":"Moor M.B.; Suter-Riniker F.; Horn M.P.; Aeberli D.; Amsler J.; M\u00f6ller B.; Njue L.M.; Medri C.; Angelillo-Scherrer A.; Borradori L.; Radonjic-Hoesli S.; Seyed Jafari S.M.; Chan A.; Hoepner R.; Bacher V.U.; Mani L.Y.; Iype J.M.; Hirzel C.; Maurer B.; Sidler D.; Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigator-initiated, single-centre, open-label study. Lancet Rheumatol  2021,3(11),e789-e797","journal-title":"Lancet Rheumatol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41581-021-00406-6","volume":"17","author":"Windpessl M.","year":"2021","unstructured":"Windpessl M.; Bruchfeld A.; Anders H.J.; Kramer H.; Waldman M.; Renia L.; Ng L.F.P.; Xing Z.; Kronbichler A.; COVID-19 vaccines and kidney disease. Nat Rev Nephrol  2021,17(5),291-293","journal-title":"Nat Rev Nephrol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"Choi B.","year":"2020","unstructured":"Choi B.; Choudhary M.C.; Regan J.; Sparks J.A.; Padera R.F.; Qiu X.; Solomon I.H.; Kuo H.H.; Boucau J.; Bowman K.; Adhikari U.D.; Winkler M.L.; Mueller A.A.; Hsu T.Y.T.; Desjardins M.; Baden L.R.; Chan B.T.; Walker B.D.; Lichterfeld M.; Brigl M.; Kwon D.S.; Kanjilal S.; Richardson E.T.; Jonsson A.H.; Alter G.; Barczak A.K.; Hanage W.P.; Yu X.G.; Gaiha G.D.; Seaman M.S.; Cernadas M.; Li J.Z.; Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med  2020,383(23),2291-2293","journal-title":"N Engl J Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/annrheumdis-2021-220088","volume":"80","author":"Friedman M.A.","year":"2021","unstructured":"Friedman M.A.; Winthrop K.L.; Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab. Ann Rheum Dis  2021,80(8),1102-1104","journal-title":"Ann Rheum Dis"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","volume":"43","author":"Friedman M.A.","year":"2017","unstructured":"Friedman M.A.; Winthrop K.L.; Vaccines and disease-modifying antirheumatic drugs. Rheum Dis Clin North Am  2017,43(1),1-13","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/ndt\/gfab174","volume":"36","author":"Bruchfeld A.","year":"2021","unstructured":"Bruchfeld A.; Kronbichler A.; Alberici F.; Fervenza F.C.; Jayne D.R.W.; Segelmark M.; Tesar V.; Szpirt W.M.; COVID-19 and ANCA-associated vasculitis: Recommendations for vaccine preparedness and the use of rituximab. Nephrol Dial Transplant  2021,36(9),1758-1760","journal-title":"Nephrol Dial Transplant"},{"key":"ref=133","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.020","author":"Kant S.","year":"2021","unstructured":"Kant S.; Azar A.; Geetha D.; Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int  2021","journal-title":"Kidney Int"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","volume":"600","author":"Pozzetto B.","year":"2021","unstructured":"Pozzetto B.; Legros V.; Djebali S.; Barateau V.; Guibert N.; Villard M.; Peyrot L.; Allatif O.; Fassier J.B.; Massardier-Pilonch\u00e9ry A.; Brengel-Pesce K.; Yaugel-Novoa M.; Denolly S.; Boson B.; Bourlet T.; Bal A.; Valette M.; Andrieu T.; Lina B.; Saker K.; Compagnon C.; Mokdad B.; d\u2019Aubarede C.; Pitiot V.; Escuret V.; Morfin F.; Trabaud M-A.; Prieux M.; Dubois V.; Josset L.; Daniel S.; Cosset F-L.; Paul S.; Defrance T.; Marvel J.; Walzer T.; Trouillet-Assant S.; Immunogenicity and efficacy of heterologous ChAdOx1\u2013BNT162b2 vaccination. Nature  2021,600(7890),701-706","journal-title":"Nature"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"van Daalen E.E.","year":"2017","unstructured":"van Daalen E.E.; Rizzo R.; Kronbichler A.; Wolterbeek R.; Bruijn J.A.; Jayne D.R.; Bajema I.M.; Rahmattulla C.; Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis  2017,76(6),1064-1069","journal-title":"Ann Rheum Dis"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"Flossmann O.","year":"2011","unstructured":"Flossmann O.; Berden A.; de Groot K.; Hagen C.; Harper L.; Heijl C.; H\u00f6glund P.; Jayne D.; Luqmani R.; Mahr A.; Mukhtyar C.; Pusey C.; Rasmussen N.; Stegeman C.; Walsh M.; Westman K.; Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis  2011,70(3),488-494","journal-title":"Ann Rheum Dis"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501323529240910015912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/234349\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501323529240910015912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:04:20Z","timestamp":1737378260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/234349\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501323529240910015912","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}